Since 2014, DreaMed has pioneered the first artificial pancreas and became the world's first company to receive FDA clearance for a smart algorithm that provides personalized treatment recommendations. Today, our cutting-edge technology is transforming diabetes management and pushing the boundaries of technology to provide expert-level care for people with diabetes everywhere.
Our Mission
Transforming diabetes management, for everyone – everywhere.
Our inspiration
In 2014, a visionary group of leading endocrinologists, engineers, and data scientists identified a critical gap between medical expertise and real-time patient needs — and seized the opportunity to transform diabetes management for everyone, everywhere.
Our Solution
DreaMed envisions a world where every person with diabetes receives expert-level care, seamlessly and effortlessly. We close the gap between rising patient demand and limited specialist availability by harnessing medical data and delivering personalized treatment - without ever compromising on quality or patient experience. Our goal is to make diabetes management so intuitive and effective that it becomes a subtle, background aspect of daily life - a non-issue.
Our Why
Access to expert medical knowledge in diabetes care remains limited, despite rising demand. Diabetes is a complex and costly condition that requires ongoing, specialized management. However, a significant shortage of endocrinology specialists makes it increasingly difficult for healthcare providers to deliver consistent, high-quality care. This shortage also constrains their ability to scale services or maintain financial sustainability, often resulting in compromised patient outcomes and missed revenue opportunities. There is an urgent need for a scalable approach to deliver specialist-level care without overextending limited clinical resources.
Our Journey
Leadership
DreaMed Leadership Team
Eran Atlas
CEO and Co-Founder
We take the way physicians are thinking, turn it into a software that can analyze data and provide a treatment recommendation as if a specialist reviewed the data and made those same recommendations. The intention was we would like to covers many as patients as possible, as many use cases possible, be able to back that up with clinical trials, be able to back it up with FDA clearance. And that's exactly what we did!
DreaMed Leadership Team
Prof. Moshe Phillip
DreaMed's Chief Science Officer, Co-Founder & Director of Endocrinology at Schneider Chidren's Medical Center.
As the shortage of diabetes experts persists globally, we continue to expand the use cases where we can unleash the power of AI to support patients and providers across all care settings. We are proud of our achievement to use AI to transform patient data into expert level treatment recommendations for yet another use case that meets FDA requirements.
